Canada markets closed

MYND Life Sciences Inc. (MYND.CN)

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
Add to watchlist
0.0450+0.0100 (+28.57%)
At close: 03:32PM EDT
Full screen
Previous Close0.0350
Open0.0350
Bid0.0200 x N/A
Ask0.0450 x N/A
Day's Range0.0350 - 0.0450
52 Week Range0.0150 - 0.1200
Volume35,000
Avg. Volume19,363
Market Cap2.152M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.1200
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    MYND Life Sciences Announces Update on Payment Obligations Under Unsecured Convertible Debentures

    MYND Life Sciences was formed to commercialize proprietary biomarker diagnostic tests and novel therapeutics for patients suffering from MDD, TRD and other neuro-inflammatory disorders Vancouver, British Columbia--(Newsfile Corp. - September 11, 2023) - MYND Life Sciences Inc. (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company") today announces it has not made its payment obligations under its unsecured convertible debentures issued on September 8, 2021 with a total principal amount of $3,000,00

  • Newsfile

    MYND Life Sciences Inc. Has Management CTO Revoked

    Vancouver, British Columbia--(Newsfile Corp. - May 9, 2023) - MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company"), a biopharmaceutical research and development company creating innovative precision medicines for patients with relentless neurological diseases, today announced details regarding its Management Cease Trade Order. In accordance with the alternative information guidelines set out in National Policy 12-203 – Management Cease Trade Orders ("NP 12-203") MYND is giving

  • Newsfile

    MYND Life Sciences Inc. Provides Default Status Report

    Vancouver, British Columbia--(Newsfile Corp. - April 25, 2023) - MYND Life Sciences (CSE: MYND) (OTCQB: MYNDF) ("MYND" or the "Company"), a biopharmaceutical research and development company creating innovative precision medicines for patients with relentless neurological diseases, today announced details regarding its Management Cease Trade Order. In accordance with the alternative information guidelines set out in National Policy 12-203 - Management Cease Trade Orders ("NP 12-203") MYND is giv